MAIA Biotechnology (MAIA) Other Working Capital Changes (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Other Working Capital Changes of -$137114.0 for Q1 2026, down 130.02% year-over-year from $456752.0 in Q1 2025, and down 157.38% quarter-over-quarter from $238952.0 in Q4 2025.
MAIA Biotechnology (MAIA) Other Working Capital Changes (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Other Working Capital Changes for 6 consecutive years, with -$137114.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Working Capital Changes fell 130.02% year-over-year to -$137114.0; the TTM figure through Mar 2026 stood at -$14100.0 (down 101.96% YoY), while the FY2025 annual figure was $579766.0, up 195.9% from the prior year.
- Other Working Capital Changes retreated to -$137114.0 in Q1 2026 per MAIA's latest filing, from $238952.0 in the prior quarter.
- Across five years, Other Working Capital Changes topped out at $456752.0 in Q1 2025 and bottomed at -$412446.0 in Q4 2022.
- Historically, Other Working Capital Changes has averaged $20731.4 across 5 years, with a median of -$31433.0 in 2024.
- On a YoY basis, Other Working Capital Changes climbed as much as 860.19% in 2025 and fell as far as 277.43% in 2025.
- MAIA Biotechnology's Other Working Capital Changes stood at -$412446.0 in 2022, then soared by 63.22% to -$151686.0 in 2023, then jumped by 79.28% to -$31433.0 in 2024, then surged by 860.19% to $238952.0 in 2025, then sank by 157.38% to -$137114.0 in 2026.
- Business Quant data shows MAIA's Other Working Capital Changes at -$137114.0 in Q1 2026, $238952.0 in Q4 2025, and -$11443.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -264,876.00 |
| Jun 30, 2026 | -264,876.00 |
| Jun 30, 2026 | -264,876.00 |
| Mar 31, 2026 | -137,114.00 |
| Mar 31, 2026 | -137,114.00 |
| Mar 31, 2026 | -137,114.00 |
| Dec 31, 2025 | 238,952.00 |
| Dec 31, 2025 | 238,952.00 |
| Dec 31, 2025 | 238,952.00 |
| Sep 30, 2025 | -11,443.00 |
| Sep 30, 2025 | -11,443.00 |
| Sep 30, 2025 | -11,443.00 |
| Jun 30, 2025 | -104,495.00 |
| Jun 30, 2025 | -104,495.00 |
| Jun 30, 2025 | -104,495.00 |
| Mar 31, 2025 | 456,752.00 |
| Mar 31, 2025 | 456,752.00 |
| Mar 31, 2025 | 456,752.00 |
| Dec 31, 2024 | -31,433.00 |
| Dec 31, 2024 | -31,433.00 |